Scholar Rock to Present at the 44th Annual J.P. Morgan Healthcare Conference

Key Terms

spinal muscular atrophy medical

A genetic condition in which the “wiring” between the spinal cord and muscles fails, causing progressive loss of muscle strength and motor skills from infancy through adulthood as the nerve cells that move muscles deteriorate. Investors pay attention because the condition creates a clear, long-term need for specialized therapies, diagnostics and ongoing care — meaning successful drugs or tests can attract premium pricing, sustained demand and significant regulatory and reimbursement scrutiny that materially affect biotech and healthcare valuations.

sma medical

A simple moving average (SMA) is a line that tracks the average price of a stock over a set number of past days, smoothing out day-to-day ups and downs so the overall trend is clearer. Think of it as the rolling average of daily temperatures that reveals whether the weather is generally warming or cooling. Investors use SMAs to judge trend direction and spot levels where price often changes course, helping inform buying, selling and risk decisions, though it is not a guarantee of future moves.

myostatin biology medical

Myostatin biology is the study of the protein myostatin and the signals it uses to limit muscle growth and control repair. For investors, it matters because drugs or therapies that block or alter myostatin act like releasing a brake on muscle development—offering potential treatments for muscle-wasting diseases, age-related decline or injury recovery—so clinical results, safety and regulatory decisions in this area can strongly affect a company’s value.

neuromuscular diseases medical

Neuromuscular diseases are a group of medical conditions that damage the nerves controlling muscles or the muscles themselves, causing weakness, poor coordination, or loss of movement—think of it as problems with the wiring or motors that make the body move. They matter to investors because they often involve clear unmet medical needs, long-term care or durable treatments, and focused patient populations, which can drive drug development, pricing power, and regulatory attention in the healthcare market.

webcast technical

A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the 44^th Annual J.P. Morgan Healthcare Conference on Monday, January 12 at 7:30 a.m. PST (10:30 a.m. EST).

A live webcast of the event will be available under the “Events and Presentations” page within the Investors section of the Scholar Rock website at http://investors.scholarrock.com. A replay of the webcast will be available for approximately 90 days.

About Scholar Rock
Scholar Rock is a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. As a global leader in myostatin biology, a field focused on proteins that regulate muscle mass, the biopharmaceutical company is named for the visual resemblance of a scholar rock to protein structures. Our commitment to unlock fundamentally different treatment approaches is powered by broad application of a proprietary platform, which has developed novel monoclonal antibodies to modulate protein growth factors with extraordinary selectivity. Scholar Rock works every day to create new possibilities for patients through its highly innovative anti-myostatin program, including opportunities in additional rare neuromuscular diseases. Learn more at ScholarRock.com and follow @ScholarRock on X and on LinkedIn.

Scholar Rock^® is a registered trademark of Scholar Rock, Inc.

Availability of Other Information About Scholar Rock
Investors and others should note that we communicate with our investors and the public using our company website www.scholarrock.com, including, but not limited to, company disclosures, investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference call transcripts and webcast transcripts, as well as on X (formerly known as Twitter) and LinkedIn. The information that we post on our website or on X (formerly known as Twitter) or LinkedIn could be deemed to be material information. As a result, we encourage investors, the media and others interested to review the information that we post there on a regular basis. The contents of our website or social media shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260105255161/en/

Scholar Rock Contacts

Investors

Laura Ekas, Ph.D.

ir@scholarrock.com

917-439-0374

Media

Molly MacLeod

media@scholarrock.com

802-579-5995

Source: Scholar Rock, Inc.